share_log

Zhejiang Medicine's (SHSE:600216) Earnings Are Of Questionable Quality

Zhejiang Medicine's (SHSE:600216) Earnings Are Of Questionable Quality

浙江医药(SHSE:600216)的收益质量值得怀疑
Simply Wall St ·  08/29 19:26

Despite posting some strong earnings, the market for Zhejiang Medicine Co., Ltd.'s (SHSE:600216) stock hasn't moved much. We did some digging, and we found some concerning factors in the details.

尽管浙江医药股份有限公司(SHSE:600216)发布了一些强劲的收益,但其股票市场波动不大。我们进行了一些调查,并在细节中发现了一些令人担忧的因素。

1724973993911
SHSE:600216 Earnings and Revenue History August 29th 2024
SHSE:600216的收益和营业收入历史记录于2024年8月29日

How Do Unusual Items Influence Profit?

非常规项目如何影响利润?

To properly understand Zhejiang Medicine's profit results, we need to consider the CN¥216m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. We can see that Zhejiang Medicine's positive unusual items were quite significant relative to its profit in the year to June 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

要正确认识浙江医药的利润结果,我们需要考虑到21,600万人民币来自飞凡项目的收益。虽然盈利增加总是不错的,但飞凡项目的大幅贡献有时会减弱我们的热情。当我们分析全球大多数上市公司时,我们发现重大的飞凡项目通常不会重复出现。而且,这正是会计术语的含义。我们可以看到,浙江医药的正面飞凡项目与其2024年6月的利润相比相当显著。其他条件不变的情况下,这可能导致法定利润对基本盈利能力的指导不准确。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让您想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看基于其估计的未来盈利能力的互动图表。

Our Take On Zhejiang Medicine's Profit Performance

我们对浙江医药的利润表现的看法

As we discussed above, we think the significant positive unusual item makes Zhejiang Medicine's earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Zhejiang Medicine's underlying earnings power is lower than its statutory profit. But at least holders can take some solace from the 13% EPS growth in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So while earnings quality is important, it's equally important to consider the risks facing Zhejiang Medicine at this point in time. At Simply Wall St, we found 3 warning signs for Zhejiang Medicine and we think they deserve your attention.

如我们上面讨论的,我们认为飞凡的显著正常项目使得浙江医药的收益成为其潜在盈利能力的不良指引。因此,我们认为很有可能浙江医药的潜在盈利能力低于其法定利润。但至少持有者可以从去年13%的每股收益增长中获得些许安慰。总而言之,如果您想正确了解该公司,就必须考虑的不仅仅是上述因素。因此,尽管收益质量很重要,但同时也必须重视当前时点面临的风险。在Simply Wall St,我们发现了浙江医药的3个警示信号,我们认为这些值得您的关注。

This note has only looked at a single factor that sheds light on the nature of Zhejiang Medicine's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

本说明仅着眼于能揭示浙江医药利润性质的单一因素。但如果您能够把注意力集中在细枝末节上,就会发现更多。例如,许多人认为高股本回报率是良好的业务经济的指标,而另一些人则喜欢“跟踪资金”并寻找内部人士在买入的股票。尽管这可能需要您做些研究,您可能会发现这个免费的公司集合,其中有许多公司宣称拥有高股本回报率,或者这份具有内部持股的股票清单会对您有所帮助。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发